Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO® study [Erratum]

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO® study [Erratum]

Minakata Y, Motegi T, Ueki J, et al. Int J Chron Obstruct Pulmon Dis. 2019;14:1789–1801.During the publication process there was an operator error where the supplementary materials, mentioned on pages 1790 and 1793, were omitted from the manuscript. Please see the supplementary materials i...

Full description

Bibliographic Details
Main Authors:	Minakata Y, Motegi T, Ueki J, Gon Y, Nakamura S, Anzai T, Hirata K, Ichinose M
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-09-01
Series:	International Journal of COPD
Online Access:	https://www.dovepress.com/erratum-effect-of-tiotropiumolodaterol-on-sedentary-and-active-peer-reviewed-article-COPD

Similar Items

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO® study
by: Minakata Y, et al.
Published: (2019-08-01)

Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity
by: Ichinose M, et al.
Published: (2018-05-01)

Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis
by: Halpin DMG, et al.
Published: (2015-02-01)

Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies
by: LaForce C, et al.
Published: (2018-06-01)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
by: Ramadan WH, et al.
Published: (2015-10-01)

Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
by: Muruganandan S, et al.
Published: (2015-06-01)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
by: Ichinose M, et al.
Published: (2018-07-01)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
by: Ichinose M, et al.
Published: (2018-10-01)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
by: Beeh KM, et al.
Published: (2016-02-01)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies
by: Ichinose M, et al.
Published: (2016-08-01)

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age
by: Ferguson GT, et al.
Published: (2016-10-01)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
by: Derom E, et al.
Published: (2016-12-01)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
by: Pelaia G, et al.
Published: (2015-10-01)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting
by: Steinmetz KO, et al.
Published: (2019-07-01)

Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study
by: Jahnz-Różyk K, et al.
Published: (2015-03-01)

Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies
by: ZuWallack R, et al.
Published: (2014-10-01)

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD
by: Feldman G, et al.
Published: (2016-04-01)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
by: Marc Miravitlles, et al.
Published: (2017-11-01)

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
by: Sauer R, et al.
Published: (2016-04-01)

Remicade® (infliximab): 20 years of contributions to science and medicine
by: Melsheimer R, et al.
Published: (2019-07-01)

Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine
by: Chen Y, et al.
Published: (2020-12-01)

The COPD assessment test correlates well with the computed tomography measurements in COPD patients in China
by: Zhang Y, et al.
Published: (2015-03-01)

Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients
by: Valipour A, et al.
Published: (2019-10-01)

Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
by: Ichinose M, et al.
Published: (2015-08-01)

Spectra Optia® Apheresis System: current insights into clinical risks and benefits
by: Klink A, et al.
Published: (2018-12-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
by: Eric Derom, et al.
Published: (2019-04-01)

A randomized multicenter Phase II study of perioperative tiotropium intervention in gastric cancer patients with chronic obstructive pulmonary disease
by: Fushida S, et al.
Published: (2015-10-01)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
by: Henrik Watz, et al.
Published: (2020-05-01)

Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study
by: Adrian Gillissen, et al.
Published: (2021-09-01)

Laser Profilometry Aiding Smart Vehicle Control
by: Cosimo Patruno, et al.
Published: (2014-12-01)

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease
by: Bai C, et al.
Published: (2017-11-01)

Association between vitamin D receptor polymorphisms and osteoporosis in patients with COPD
by: Kim SW, et al.
Published: (2015-09-01)

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
by: van Boven JF, et al.
Published: (2016-09-01)

Relationship Between Proteinase with a Disintegrin and a Metalloproteinase Domain-9 (ADAM9), Inflammation, Airway Remodeling, and Emphysema in COPD Patients
by: Cui L, et al.
Published: (2020-12-01)

Tiotropium HandiHaler&reg; in the treatment of COPD: A safety review
by: Steven Kesten, et al.
Published: (2009-10-01)

Association analysis of polymorphisms in STARD6 and near ECHDC3 in Alzheimer’s disease patients carrying the APOE ε4 Allele
by: Yin J, et al.
Published: (2019-01-01)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
by: Gao J, et al.
Published: (2015-04-01)

Cannot write session to /tmp/vufind_sessions/sess_pl8kq965hcls6uli1jmkagomc2